About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

PH
Welcome back then,any news.

according to CT news on ZYC300 write up out soon. taken long enough

PH so far u have managed to get 90% of what u say wrong ,so i guess this is more zzzzzzzzz.

I agree with this post from the other side a bit of averaging down and wait.

Strangely this stock has taken an identical path to Forum Energy over the last eight months. Both released fantastic news late September and to date not a dickie bird has been heard from either. Forum rose sharply yesterday on whispers that news is about to break. Let's hope we do not lag too far behind.

On far too many occasions I've watched my investments collapse after being 100% convinced I have bought into an immediate winner. I eventually call time and no sooner have I sold out then the very same shares start motoring upwards. Is this all coincidence I keep asking myself?. After years of experience I have learnt the answer is NO, for this is the way the market makers operate.

They trash all microcap shares after there has been an initial wave of buying and will hold the shares down for months and months on end. However if the company is of sound management and of sound quality the shares will eventually recover. If the value of the company falls too low then other companies will take an interest in them. But an important thing to remember is that in order to take maximum advantage of the shareprice collapse you have to average down and wait.

driver, i tend to agree , i have just put mine in the bottom draw and one day !!!! : )

thefordprefect - 17 May'07 - 13:07 - 17943 of 17944


http://www.osip.com/OSI_027
OSI-027 is a next generation mammalian target of rapamycin (mTOR) kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR. This dual TORC1 and TORC2 activity differentiates our compound from rapamycin and the various related analogs, or rapalogs, that are currently in clinical development in that these molecules only inhibit TORC1 activity. In addition, researchers at OSI have found that the combination of an EGFR inhibitor, like Tarceva, with an inhibitor of mTOR is synergistic in certain tumor cell lines. The Company expects to file an IND for OSI-027 before the end of the fourth quarter of 2007.


http://www.wipo.int/pctdb/en/wo.jsp?wo=2003027671
Inventors: HAYES, Ian [GB/IE]; EiRx Therapeutics Ltd, Cork Airport Business Park, Kinsale Road, Cork (IE).
KROEMER, Guido [FR/FR]; Le Centre National de la Recherche Scientifique, 3 rue Michel-Agne, F-75794 Paris Cedex 16 (FR).
FERRI, Karine [FR/FR]; Le Centre National de la Recherche Scientifique, 3 rue Michel-Agne, F-75794 Paris Cedex 16 (FR).
CASTEDO, Maria [FR/FR]; Le Centre National de la Recherche Scientifique, 3 Rue Michel-Agne, F-75794 Paris Ceded 16 (FR).
Agent: MASCHIO, Antonio; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).
Priority Data: 0123025.9 25.09.2001 GB

Title: APOPTOSIS

Abstract: The present invention relates to the modulation of apoptosis, in particular it relates to the use of mTOR in the modulation of syncitial apoptosis. A method for the identification of further molecules involved in apoptosis, and the use mTOR in the treatment of disease are also disclosed. In addition, assays associated with the identification of such molecules are disclosed.


Cheers, Mike

Yawn !!!

is yesterdays share magazine

EiRx Therapeutics (ERX:AIM) Interims PTP: -0.9m (-0.9m) Divi: n/a (n/a)
Trials of the companys breast cancer product ERX3722 showed a 50% reduction in
tumour size, which it says endorses its decision to change its business model from
a research services company to a drug discoverer.
It discovered ERX3722 using its EnPad candidate screening technology and
believes this is capable of developing more products targeting different genes and
tumour types.
A share placing in September raised 500,000 but it is now looking for opportunities
such as grant funding, partnering deals with larger businesses and M&A
options to help it progress. Shares have been on a downward spiral for the last six
months but they should recover if it is successful in securing a deal.
■ Shares says: Needs a deal to help advance its technology.

Sounds Good

well we know they were in talks for a JV a good while back.. but dont know whats holding it all up

Nice write up PH

well we have already been aware they have been in negotiations for some time.. just wish we knew whats holding it all up

OSI webcast tomorrow should have news on the osi-027, as I understand this is the one that belongs to us

A bit of blue makes a change.

it does !! still need something soon me finks !!

Disappointing to say the least but life goes on at ERX.

These four kinases rejoin the panel of apoptosis targets currently subject to collaborative discussions with other parties.'

Contract Update

http://moneyam.uk-wire.com/cgi-bin/articles/200705251455062749X.html

This will be the big one, still accumulating.


19 September 2006

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in
animal studies

'A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant' said
Professor Tom Cotter, founder and CSO of EiRx. 'We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

Across the seven major markets, 443,000 women were estimated to have developed
breast cancer in 2004, with an estimated 112,000 dying from the disease. The
incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

sp coming back.

Plenty left.

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Left alone :-(